Trial Profile

A phase III trial to evaluate safety and efficacy of administering dasiglucagon via a pump

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasiglucagon (Primary)
Indications Congenital hyperinsulinism
Focus Registrational; Therapeutic Use
Sponsors Zealand Pharma

Most Recent Events

14 May 2020 According to a Zealand Pharma media release, results from the trial are expected in 2020.
02 Apr 2020 According to a Zealand Pharma media release, There has been minimal impact to patients currently enrolled due to the high unmet medical need of their treatments and the availability of innovative tools to digitally monitor and manage patients.
11 Mar 2020 Status changed from planning to recruiting, according to an Zealand Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com